StockNews.com Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to Hold

StockNews.com upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a sell rating to a hold rating in a research note released on Friday.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Aclaris Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $11.00.

Aclaris Therapeutics Price Performance

Shares of ACRS opened at $3.14 on Friday. Aclaris Therapeutics has a one year low of $0.77 and a one year high of $3.54. The company has a market cap of $224.29 million, a P/E ratio of -6.15 and a beta of 0.10. The firm has a 50 day simple moving average of $1.49 and a two-hundred day simple moving average of $1.30.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. The firm had revenue of $4.35 million for the quarter, compared to analyst estimates of $8.31 million. On average, analysts expect that Aclaris Therapeutics will post -0.65 earnings per share for the current fiscal year.

Institutional Trading of Aclaris Therapeutics

Institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Aclaris Therapeutics in the first quarter worth $39,000. SG Americas Securities LLC boosted its position in Aclaris Therapeutics by 69.5% during the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 13,461 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Aclaris Therapeutics by 5,265.1% during the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 61,602 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Aclaris Therapeutics during the second quarter valued at $119,000. Finally, Assenagon Asset Management S.A. bought a new stake in Aclaris Therapeutics during the third quarter valued at $214,000. Institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.